Toll Free Helpline (India): 1800 1234 070

Rest of World: +91-9810852116

NAAS RATING: 5.23, Impact Factor: RJIF 5.98 | Free Publication Certificate
updates
NAAS Rating: 5.23 new
Vol. 7, Issue 8 (2018)

Impact on pharmacokinetics of erlotinib by meloxicam and metformin administration in SCID mice

Author(s):
Satish D Patel, Urvesh D Patel, Kamlesh A Sadariya, Aswin M Thaker, Shailesh K Bhavsar and Harilal Patel
Abstract:
The study was carried out to evaluate the impact of meloxicam and metformin administration on pharmacokinetics of erlotinib in SCID mice. The plasma concentration of erlotinib was assayed by LC-MS/MS. Following oral administration of erlotinib as single drug in male SCID mice, the mean values of peak plasma drug concentration (Cmax), time of maximum concentration (Tmax), area under plasma drug concentration-time curve (AUC0-¥), volume of distribution (Vz), half-life (t½) and total body clearance (Cl) were 17272.59 ± 640.80 ng/ml, 0.29 ± 0.09 h, 84784.69 ± 3209.24 ng.h/ml, 3083.37 ± 247.42 ml, 6.08 ± 0.59 h and 356.48 ± 14.03 ml/hr, respectively. Significant alteration in area under curve and total body clearance of erlotinib were observed when administered along with metformin as well as meloxicam and metformin in SCID mice. Thus, concomitant administration of these drugs for prolong period requires close therapeutic monitoring for potential pharmacokinetic drug interaction. However, effect of long term administration of metformin and meloxicam on pharmacokinetics of erlotinib in mice needs to be evaluated.
Pages: 432-436  |  242 Views  8 Downloads
How to cite this article:
Satish D Patel, Urvesh D Patel, Kamlesh A Sadariya, Aswin M Thaker, Shailesh K Bhavsar, Harilal Patel. Impact on pharmacokinetics of erlotinib by meloxicam and metformin administration in SCID mice. Pharma Innovation 2018;7(8):432-436.
The Pharma Innovation Journal